CANC vs. BBOT

Last updated Jun 24, 2026

CANC (Tema Oncology ETF) is Health & Biotech Equities fund actively managed by Tema, while BBOT (BridgeBio Oncology Therapeutics, Inc) is a stock. At a 0.35 correlation, their price movements are largely independent.

Performance

CANC vs. BBOT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tema Oncology ETF (CANC) and BridgeBio Oncology Therapeutics, Inc (BBOT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CANC achieves a 11.49% return, which is significantly higher than BBOT's -40.10% return.

CANC

• 1D: 1.64%
• 1M: 1.56%
• YTD: 11.49%
• 6M: 9.19%
• 1Y: 56.88%
• 3Y*: 132.65%
• 5Y*: —
• 10Y*: —

BBOT

• 1D: -4.70%
• 1M: -12.28%
• YTD: -40.10%
• 6M: -37.13%
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CANC vs. BBOT - Yearly Performance Comparison

	2026 (YTD)	2025
CANC Tema Oncology ETF	11.49%	36.99%
BBOT BridgeBio Oncology Therapeutics, Inc	-40.10%	22.75%

Correlation

The correlation between CANC and BBOT is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (All Time) Calculated using the full available price history since Aug 12, 2025	0.35

Return for Risk

CANC vs. BBOT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CANC

CANC Risk / Return Rank: 85
CANC Sharpe Ratio Rank: 85
CANC Sortino Ratio Rank: 86
CANC Omega Ratio Rank: 74
CANC Calmar Ratio Rank: 93
CANC Martin Ratio Rank: 85

BBOT

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CANC vs. BBOT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Tema Oncology ETF (CANC) and BridgeBio Oncology Therapeutics, Inc (BBOT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CANC	BBOT	Difference
Sharpe ratio: Return per unit of total volatility	2.52	—	—
Sortino ratio: Return per unit of downside risk	3.54	—	—
Omega ratio: Gain probability vs. loss probability	1.40	—	—
Calmar ratio: Return relative to maximum drawdown	6.15	—	—
Martin ratio: Return relative to average drawdown	16.71	—	—

Drawdowns

CANC vs. BBOT - Drawdown Comparison

The maximum CANC drawdown since its inception was -97.53%, which is greater than BBOT's maximum drawdown of -48.14%. Use the drawdown chart below to compare losses from any high point for CANC and BBOT.

Drawdown Indicators

	CANC	BBOT	Difference
Max Drawdown Largest peak-to-trough decline	-97.53%	-48.14%	-49.39%
Max Drawdown (1Y) Largest decline over 1 year	-9.30%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-30.27%	—	—
Current Drawdown Current decline from peak	-53.78%	-45.38%	-8.40%
Average Drawdown Average peak-to-trough decline	-72.94%	-20.56%	-52.38%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.41%	—	—

Volatility

Volatility by Period

	CANC	BBOT	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.60%	—	—
Volatility (6M) Calculated over the trailing 6-month period	16.94%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	22.72%	70.40%	-47.68%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	278.65%	70.40%	+208.25%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	278.65%	70.40%	+208.25%

Dividends

CANC vs. BBOT - Dividend Comparison

CANC's dividend yield for the trailing twelve months is around 0.05%, while BBOT has not paid dividends to shareholders.

Position	TTM	2025	2024	2023
BBOT BridgeBio Oncology Therapeutics, Inc	0.00%	0.00%	0.00%	0.00%
CANC Tema Oncology ETF	0.05%	0.06%	3.00%	0.56%

Frequently Asked Questions

Can I hold both CANC and BBOT in my portfolio?

CANC and BBOT have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.